Skip to main content
Erschienen in: Clinical Orthopaedics and Related Research® 11/2010

01.11.2010 | Symposium: Highlights of the ISOLS/MSTS 2009 Meeting

Does Increased Rate of Limb-sparing Surgery Affect Survival in Osteosarcoma?

verfasst von: Miguel A. Ayerza, MD, Germán L. Farfalli, MD, Luis Aponte-Tinao, MD, D. Luis Muscolo, MD

Erschienen in: Clinical Orthopaedics and Related Research® | Ausgabe 11/2010

Einloggen, um Zugang zu erhalten

Abstract

Background

The emergence of limb salvage surgery as an option for patients with osteosarcoma is attributable to preoperative chemotherapy and advancements in musculoskeletal imaging and surgical technique. While the indications for limb salvage have greatly expanded it is unclear whether limb salvage affects overall survival.

Questions/purposes

We asked whether over the past three decades limb-sparing procedures in high-grade osteosarcoma had increased, and whether this affected survival and ultimate amputation.

Methods

We retrospectively reviewed 251 patients with high-grade osteosarcoma treated from 1980 to 2004 with a multidisciplinary approach, including neoadjuvant chemotherapy. We compared survival rates, limb-salvage treatment, and amputation after limb-sparing procedure during three different periods of time. Fifty-three patients were treated from 1980 to 1989, 97 from 1990 to 1999, and 101 from 2000 to 2004. Thirty-seven patients were treated with primary amputations and 214 with primary limb salvage.

Results

The 5-year survival rate in the first period was 36%, whereas in the 1990s, it was 60% and 67% from 2000–2004. Limb salvage surgery rate in the 1980s was 53% (28 of 53), whereas in the 1990s, it was 91% (88 of 97) and 97% from 2000–2004 (98 of 101). In the limb salvage group, 22 of the 214 patients (10%) required secondary amputation; the final limb salvage rate in the first period was 36% (19 of 53), whereas in the 1990s, it was 81% (79 of 97) and 93% from 2000–2004 (94 of 101).

Conclusions

Patients with osteosarcoma treated in the last two periods had higher rates of limb salvage treatment and survival, with lower secondary amputation.

Level of Evidence

Level III, prognostic study. See the Guidelines for Authors for a complete description of levels of evidence.
Literatur
1.
Zurück zum Zitat Aksnes LH, Bauer HC, Jebsen NL, Follerås G, Allert C, Haugen GS, Hall KS. Limb-sparing surgery preserves more function than amputation: a Scandinavian sarcoma group study of 118 patients. J Bone Joint Surg Br. 2008;90:786–794.CrossRefPubMed Aksnes LH, Bauer HC, Jebsen NL, Follerås G, Allert C, Haugen GS, Hall KS. Limb-sparing surgery preserves more function than amputation: a Scandinavian sarcoma group study of 118 patients. J Bone Joint Surg Br. 2008;90:786–794.CrossRefPubMed
2.
Zurück zum Zitat Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi A, Forni C, Bertoni F, Versari M, Pignotti E. Osteosarcoma of the limb. J Bone Joint Surg Br. 2002;84:88–92.CrossRefPubMed Bacci G, Ferrari S, Lari S, Mercuri M, Donati D, Longhi A, Forni C, Bertoni F, Versari M, Pignotti E. Osteosarcoma of the limb. J Bone Joint Surg Br. 2002;84:88–92.CrossRefPubMed
3.
Zurück zum Zitat Bacci G, Ferrari S, Longhi A, Forni C, Bertoni F, Fabbri N, Zavatta M, Versari M. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother. 2001;13:93–99.PubMed Bacci G, Ferrari S, Longhi A, Forni C, Bertoni F, Fabbri N, Zavatta M, Versari M. Neoadjuvant chemotherapy for high grade osteosarcoma of the extremities: long-term results for patients treated according to the Rizzoli IOR/OS-3b protocol. J Chemother. 2001;13:93–99.PubMed
4.
Zurück zum Zitat Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, Serra M, Briccoli A, Balladelli A, Picci P. Local recurrence and local control of non-metastatic osteosarcoma of the extremities. A 27-year experience in a single institution. J Surg Oncol. 2007;96:118–123.CrossRefPubMed Bacci G, Forni C, Longhi A, Ferrari S, Mercuri M, Bertoni F, Serra M, Briccoli A, Balladelli A, Picci P. Local recurrence and local control of non-metastatic osteosarcoma of the extremities. A 27-year experience in a single institution. J Surg Oncol. 2007;96:118–123.CrossRefPubMed
5.
Zurück zum Zitat Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Fifteen year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–1161.CrossRefPubMed Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy. Fifteen year experience in 789 patients treated at a single institution. Cancer. 2006;106:1154–1161.CrossRefPubMed
6.
Zurück zum Zitat Bruland OS, Høifødt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res. 2005;11:4666–4673.CrossRefPubMed Bruland OS, Høifødt H, Saeter G, Smeland S, Fodstad O. Hematogenous micrometastases in osteosarcoma patients. Clin Cancer Res. 2005;11:4666–4673.CrossRefPubMed
7.
Zurück zum Zitat Dahlin DC, Coventry MB. Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am. 1967;49:101–110.PubMed Dahlin DC, Coventry MB. Osteogenic sarcoma. A study of six hundred cases. J Bone Joint Surg Am. 1967;49:101–110.PubMed
8.
Zurück zum Zitat Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5:21–26.PubMed Eilber F, Giuliano A, Eckardt J, Patterson K, Moseley S, Goodnight J. Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial. J Clin Oncol. 1987;5:21–26.PubMed
9.
Zurück zum Zitat Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9–24.PubMed Enneking WF. A system of staging musculoskeletal neoplasms. Clin Orthop Relat Res. 1986;204:9–24.PubMed
10.
Zurück zum Zitat Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, Bacci G. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity. An analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol. 2001;12:1145–1150.CrossRefPubMed Ferrari S, Bertoni F, Mercuri M, Picci P, Giacomini S, Longhi A, Bacci G. Predictive factors of disease-free survival for non-metastatic osteosarcoma of the extremity. An analysis of 300 patients treated at the Rizzoli Institute. Ann Oncol. 2001;12:1145–1150.CrossRefPubMed
11.
Zurück zum Zitat Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G. Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity. A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845–8852.CrossRefPubMed Ferrari S, Smeland S, Mercuri M, Bertoni F, Longhi A, Ruggieri P, Alvegard TA, Picci P, Capanna R, Bernini G, Müller C, Tienghi A, Wiebe T, Comandone A, Böhling T, Del Prever AB, Brosjö O, Bacci G, Saeter G. Italian and Scandinavian Sarcoma Groups. Neoadjuvant chemotherapy with high-dose ifosfamide, high-dose methotrexate, cisplatin, and doxorubicin for patients with localized osteosarcoma of the extremity. A joint study by the Italian and Scandinavian Sarcoma Groups. J Clin Oncol. 2005;23:8845–8852.CrossRefPubMed
12.
Zurück zum Zitat Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP; Pediatric Oncology Group. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–1580.CrossRefPubMed Goorin AM, Schwartzentruber DJ, Devidas M, Gebhardt MC, Ayala AG, Harris MB, Helman LJ, Grier HE, Link MP; Pediatric Oncology Group. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–1580.CrossRefPubMed
13.
Zurück zum Zitat Hawkins D, Arndt C. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer. 2003;98:2447–2456.CrossRefPubMed Hawkins D, Arndt C. Pattern of disease recurrence and prognostic factors in patients with osteosarcoma treated with contemporary chemotherapy. Cancer. 2003;98:2447–2456.CrossRefPubMed
14.
Zurück zum Zitat Honegger HP, Cserhati MD, Exner GU, von Hochstetter A, Groscurth P. Zürich experience with preoperative, high dose methotrexate-containing chemotherapy in patients with extremity osteosarcomas (OSA). Ann Oncol. 1991;2:489–494.PubMed Honegger HP, Cserhati MD, Exner GU, von Hochstetter A, Groscurth P. Zürich experience with preoperative, high dose methotrexate-containing chemotherapy in patients with extremity osteosarcomas (OSA). Ann Oncol. 1991;2:489–494.PubMed
15.
Zurück zum Zitat Huvos AG. Osteogenic Sarcoma. Bone Tumors. Diagnosis, Treatment and Prognosis. 2nd ed. Philadelphia, PA: WB Saunders; 1991:85–276. Huvos AG. Osteogenic Sarcoma. Bone Tumors. Diagnosis, Treatment and Prognosis. 2nd ed. Philadelphia, PA: WB Saunders; 1991:85–276.
16.
Zurück zum Zitat Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH. MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy. A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112–128.CrossRefPubMed Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC, Memon MA, Weeden S, Uscinska BM, van Glabbeke M, Kirkpatrick A, Hauben EI, Craft AW, Taminiau AH. MRC BO06 and EORTC 80931 collaborators; European Osteosarcoma Intergroup. Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy. A randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst. 2007;99:112–128.CrossRefPubMed
17.
Zurück zum Zitat Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res. 1991;270:8–14.PubMed Link MP, Goorin AM, Horowitz M, Meyer WH, Belasco J, Baker A, Ayala A, Shuster J. Adjuvant chemotherapy of high-grade osteosarcoma of the extremity. Updated results of the Multi-Institutional Osteosarcoma Study. Clin Orthop Relat Res. 1991;270:8–14.PubMed
18.
Zurück zum Zitat Mercuri M, Capanna R, Manfrini M, Bacci G, Picci P, Ruggieri P, Ferruzzi A, Ferraro A, Donati D, Biagini R, de Maio M, Cazzola A, Campanacci M. The management of malignant bone tumors in children and adolescents. Clin Orthop Relat Res. 1991;264:156–168.PubMed Mercuri M, Capanna R, Manfrini M, Bacci G, Picci P, Ruggieri P, Ferruzzi A, Ferraro A, Donati D, Biagini R, de Maio M, Cazzola A, Campanacci M. The management of malignant bone tumors in children and adolescents. Clin Orthop Relat Res. 1991;264:156–168.PubMed
19.
Zurück zum Zitat Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma—the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163–2192.CrossRefPubMed Rosen G, Marcove RC, Caparros B, Nirenberg A, Kosloff C, Huvos AG. Primary osteogenic sarcoma—the rationale for preoperative chemotherapy and delayed surgery. Cancer. 1979;43:2163–2192.CrossRefPubMed
20.
Zurück zum Zitat Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am. 1986;68:1331–1337.PubMed Simon MA, Aschliman MA, Thomas N, Mankin HJ. Limb-salvage treatment versus amputation for osteosarcoma of the distal end of the femur. J Bone Joint Surg Am. 1986;68:1331–1337.PubMed
21.
Zurück zum Zitat Sluga M, Windhager R, Lang S, Heinzl H, Bielack S, Kotz R. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop Relat Res. 1999;358:120–127.CrossRefPubMed Sluga M, Windhager R, Lang S, Heinzl H, Bielack S, Kotz R. Local and systemic control after ablative and limb sparing surgery in patients with osteosarcoma. Clin Orthop Relat Res. 1999;358:120–127.CrossRefPubMed
22.
Zurück zum Zitat Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2124–2135.CrossRefPubMed Stiller CA, Bielack SS, Jundt G, Steliarova-Foucher E. Bone tumours in European children and adolescents, 1978–1997. Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 2006;42:2124–2135.CrossRefPubMed
23.
Zurück zum Zitat Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer. 1997;79:411–415.CrossRefPubMed Uchida A, Myoui A, Araki N, Yoshikawa H, Shinto Y, Ueda T. Neoadjuvant chemotherapy for pediatric osteosarcoma patients. Cancer. 1997;79:411–415.CrossRefPubMed
Metadaten
Titel
Does Increased Rate of Limb-sparing Surgery Affect Survival in Osteosarcoma?
verfasst von
Miguel A. Ayerza, MD
Germán L. Farfalli, MD
Luis Aponte-Tinao, MD
D. Luis Muscolo, MD
Publikationsdatum
01.11.2010
Verlag
Springer-Verlag
Erschienen in
Clinical Orthopaedics and Related Research® / Ausgabe 11/2010
Print ISSN: 0009-921X
Elektronische ISSN: 1528-1132
DOI
https://doi.org/10.1007/s11999-010-1423-4

Weitere Artikel der Ausgabe 11/2010

Clinical Orthopaedics and Related Research® 11/2010 Zur Ausgabe

Arthropedia

Grundlagenwissen der Arthroskopie und Gelenkchirurgie. Erweitert durch Fallbeispiele, Videos und Abbildungen. 
» Jetzt entdecken

Update Orthopädie und Unfallchirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.